Ibrutinib repurposing : from B-cell malignancies to solid tumors
Massó Vallés, Daniel (Vall d'Hebron Institut d'Oncologia)
Jauset González, Toni (Vall d'Hebron Institut d'Oncologia)
Soucek, Laura (Vall d'Hebron Institut d'Oncologia)
Universitat Autònoma de Barcelona.
Departament de Bioquímica i de Biologia Molecular
Date: |
2016 |
Abstract: |
Ibrutinib (Imbruvica®, also known as PCI-32765) is a first-in-class, irreversible small-molecule inhibitorof Bruton's Tyrosine Kinase (BTK) that binds covalently to cysteine C481 within the ATP-binding pocket. Since BTK is a Tec family non-receptor tyrosine kinase that is specifically required for B-cell antigen receptor (BCR) signaling, ibrutinib was initially developed for the treatment of B-cell malignancies. Currently, it is approved for first-line treatment of chronic lymphocytic leukemia, and for the treatment of mantle-cell lymphoma and Waldenström's macroglobulinemia patients that have received at least one previous therapy. |
Grants: |
Instituto de Salud Carlos III CP10-00656
|
Rights: |
Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. |
Language: |
Anglès |
Document: |
Article ; recerca ; Versió publicada |
Subject: |
Ibrutinib ;
Drug repurposing ;
Solid tumors ;
Inflammation ;
BTK |
Published in: |
Oncoscience, Vol. 3, Num. 5-6 (may 2016) , p. 147-148, ISSN 2331-4737 |
DOI: 10.18632/oncoscience.310
PMID: 27489860
The record appears in these collections:
Articles >
Research articlesArticles >
Published articles
Record created 2018-02-07, last modified 2023-03-07